Re:Cognition Health has launched CognitionCheck, a groundbreaking cognitive health and memory assessment designed to support earlier detection of Alzheimer’s disease and other causes of memory decline in adults aged 50 and over.
The launch responds to growing demand for earlier, more proactive insight into cognitive health. Research shows that 4 in 5 people said they would want to know if they had Alzheimer’s disease before symptoms appear. Alzheimer’s is the most common form of dementia, making up 60-80% of one million dementia cases in the UK, predicted to grow to 1.4 million by 2040. CognitionCheck is designed to meet this moment – empowering individuals with the knowledge and clinical support needed to manage their own and their loved ones’ brain health proactively.
Early diagnosis is increasingly critical, as new disease-modifying treatments for Alzheimer’s disease are most effective when introduced at the earliest stages.
A new standard in cognitive health assessment
CognitionCheck brings together four advanced diagnostic tools within a single, streamlined pathway, combining clinical expertise with emerging technologies to deliver a more complete picture of brain health. A key element of the new assessment is the p-Tau217 blood test, a highly sensitive biomarker that can provide additional information on whether even mild memory symptoms are linked to early-stage Alzheimer’s disease.
Key elements include:
· A detailed MRI brain scan to assess structural changes, provided byin partnership with Scan.com
· AI-driven cognitive testing to detect subtle changes in memory and thinking
· The p-Tau217 blood biomarker to support early identification of Alzheimer’s pathology
· Specialist consultation with an experienced Re:Cognition Health cognitive physician to interpret results and guide next steps
This integrated approach allows individuals to understand not only whether changes are present, but the underlying cause and the most appropriate clinical pathway forward.
Early diagnosis is imperative to treatment
Memory concerns can arise from a range of causes, many of which are treatable or reversible if identified early. Establishing the underlying cause is therefore critical in determining the most appropriate course of action.
Emer MacSweeney, CEO and Medical Director at Re:Cognition Health, comments: “Early diagnosis is more crucial today, than ever. With new treatments that slow Alzheimer’s and other neurodegenerative conditions, identifying changes before symptoms become severe allows people to benefit from these therapies. Too often, cognitive decline is advancing ahead of overall physical health, and in many cases, the brain is dying before the body. This assessment combines advanced cognitive testing, brain imaging and blood biomarkers with expert clinical interpretation, empowering individuals to take proactive steps to optimise their brain health.”
Accessible, nationwide assessment
CognitionCheck is designed to be accessible and convenient, with flexible scheduling and a seamless patient journey. MRI scans are delivered in partnership with Scan.com, a tech-enabled diagnostics platform that powers the entire imaging pathway, providing convenient access to over 300+ imaging centres, nationwide.
Dr Lizzie Tuckey, Managing Director at Scan.com, said: “We’re proud to partner with Re:Cognition Health on this state-of-the-art CognitionCheck assessment. The easier a brain MRI is to access, the sooner patients get answers and the more options they have for treatment and planning. By expanding access to imaging services for Re:Cognition Health patients, we’re removing barriers to earlier diagnosis and supporting healthier minds for years to come.”
Back
